Buformin

Buformin is a member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect. Among its listed roles, it functions as a radiosensitizing agent, a geroprotector, an antiviral agent, a hypoglycemic agent and an antineoplastic agent. Functionally, it is related to biguanide. Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin. It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. Buformin is an agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Buformin is not metabolized and is excreted in the urine. This agent has been withdrawn from the market due to its elevated risk of lactic acidosis. An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation. It is grouped under the following drug class(es): Biguanides and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include 1-Butylbiguanide, Buformine, Butylbiguanide and Butyldiguanide. Its PubChem CID is 2468.

CAS No 692-13-7
Molecular Formula C6H15N5
Molecular Weight 157.22 g/mol
Synonyms 2-butyl-1-(diaminomethylidene)guanidine

Frequently Asked Questions